Dynamical histories of planetary systems, as well as the atmospheric evolution of highly irradiated planets, can be studied by characterizing the ultra-short-period planet population, which the TESS ...mission is particularly well suited to discover. Here, we report on the follow-up of a transit signal detected in the TESS sector 19 photometric time series of the M3.0 V star TOI-1685 (2MASS J04342248+4302148). We confirm the planetary nature of the transit signal, which has a period of
P
b
= 0.6691403
−0.0000021
+0.0000023
d, using precise radial velocity measurements taken with the CARMENES spectrograph. From the joint photometry and radial velocity analysis, we estimate the following parameters for TOI-1685 b: a mass of
M
b
= 3.78
−0.63
+0.63
M
⊕
, a radius of
R
b
= 1.70
−0.07
+0.07
R
⊕
, which together result in a bulk density of
ρ
b
= 4.21
−0.82
+0.95
g cm
−3
, and an equilibrium temperature of
T
eq
= 1069
−16
+16
K. TOI-1685 b is the least dense ultra-short-period planet around an M dwarf known to date. TOI-1685 b is also one of the hottest transiting super-Earth planets with accurate dynamical mass measurements, which makes it a particularly attractive target for thermal emission spectroscopy. Additionally, we report with moderate evidence an additional non-transiting planet candidate in the system, TOI-1685 c, which has an orbital period of
P
c
= 9.02
−0.12
+0.10
d.
Although the majority of radial velocity detected planets have been found orbiting solar-type stars, a fraction of them have been discovered around giant stars. These planetary systems have revealed ...different orbital properties when compared to solar-type star companions. In particular, radial velocity surveys have shown that there is a lack of giant planets in close-in orbits around giant stars, in contrast to the known population of hot Jupiters orbiting solar-type stars. It has been theorized that the reason for this distinctive feature in the semimajor axis distribution is the result of the stellar evolution and/or that it is due to the effect of a different formation/evolution scenario for planets around intermediate-mass stars. However, in the past few years a handful of transiting short-period planets (P ≲ 10 days) have been found around giant stars, thanks to the high-precision photometric data obtained initially by the Kepler mission, and later by its two-wheel extension K2. These new discoveries have allowed us for the first time to study the orbital properties and physical parameters of these intriguing and elusive substellar companions. In this paper we report on an independent discovery of a transiting planet in field 10 of the K2 mission, also reported recently by Grunblatt et al. (2017, AJ, 154, 254). The host star has recently evolved to the giant phase, and has the following atmospheric parameters: Teff = 4878 ± 70 K, log g = 3.289 ± 0.004, and Fe/H = −0.11 ± 0.05 dex. The main orbital parameters of K2-132 b, obtained with all the available data for the system are: P = 9.1708 ± 0.0025 d, e = 0.290 ± 0.049, Mp = 0.495 ± 0.007 MJ and Rp = 1.089 ± 0.006 RJ. This is the fifth known planet orbiting any giant star with a < 0.1, and the most eccentric one among them, making K2-132 b a very interesting object.
Transarterial radioembolization with yttrium-90 (Y-90 TARE) microspheres therapy has demonstrated positive clinical benefits for the treatment of liver metastases from colorectal cancer (lmCRC). This ...study aims to conduct a systematic review of the available economic evaluations of Y-90 TARE for lmCRC.
English and Spanish publications were identified from PubMed, Embase, Cochrane, MEDES health technology assessment agencies, and scientific congress databases published up to May 2021. The inclusion criteria considered only economic evaluations; thus, other types of studies were excluded. Purchasing-power-parity exchange rates for the year 2020 ($US PPP) were applied for cost harmonisation.
From 423 records screened, seven economic evaluations (2 cost-analyses CA and 5 cost-utility-analyses CUA) were included (6 European and 1 USA). All included studies (n = 7) were evaluated from a payer and the social perspective (n = 1). Included studies evaluated patients with unresectable liver-predominant metastases of CRC, refractory to chemotherapy (n = 6), or chemotherapy-naïve (n = 1). Y-90 TARE was compared to best supportive care (BSC) (n = 4), an association of folinic acid, fluorouracil and oxaliplatin (FOLFOX) (n = 1), and hepatic artery infusion (HAI) (n = 2). Y-90 TARE increased life-years gained (LYG) versus BSC (1.12 and 1.35 LYG) and versus HAI (0.37 LYG). Y-90 TARE increased the quality-adjusted-life-year (QALY) versus BSC (0.81 and 0.83 QALY) and versus HAI (0.35 QALY). When considering a lifetime horizon, Y-90 TARE reported incremental cost compared to BSC (range 19,225 to 25,320 $US PPP) and versus HAI (14,307 $US PPP). Y-90 TARE reported incremental cost-utility ratios (ICURs) between 23,875 $US PPP/QALY to 31,185 $US PPP/QALY. The probability of Y-90 TARE being cost-effective at £ 30,000/QALY threshold was between 56% and 57%.
Our review highlights that Y-90 TARE could be a cost-effective therapy either as a monotherapy or when combined with systemic therapy for treating ImCRC. However, despite the current clinical evidence on Y-90 TARE in the treatment of ImCRC, the global economic evaluation reported for Y-90 TARE in ImCRC is limited (n = 7), therefore, we recommend future economic evaluations on Y-90 TARE versus alternative options in treating ImCRC from the societal perspective.
Abstract
Background
Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a ...systematic review of the available economic evaluations of TARE for the treatment of HCC.
Methods
The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP).
Results
Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY.
Conclusions
Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.
We report the discovery of four transiting F-M binary systems with companions between 0.1 and 0.2 M in mass by the HATSouth survey. These systems have been characterized via a global analysis of the ...HATSouth discovery data, combined with high-resolution radial velocities and accurate transit photometry observations. We determined the masses and radii of the component stars using a combination of two methods: isochrone fitting of spectroscopic primary star parameters and equating spectroscopic primary star rotation velocity with spin-orbit synchronization. These new very low mass companions are HATS550-016B (
,
), HATS551-019B (
,
), HATS551-021B (
,
) and HATS553-001B (
,
). We examine our sample in the context of the radius anomaly for fully convective low-mass stars. Combining our sample with the 13 other well-studied very low mass stars, we find a tentative 5 per cent systematic deviation between the measured radii and theoretical isochrone models.
ABSTRACT
We present results of the analysis of light and radial velocity (RV) curves of eight detached eclipsing binaries observed by the All-Sky Automated Survey, which we have followed up with ...high-resolution spectroscopy, and were later observed by the Keplersatellite as part of the K2mission. The RV measurements came from spectra obtained with OAO-188/HIDES, MPG-2.2 m/FEROS, SMARTS 1.5 m/CHIRON, Euler/CORALIE, ESO-3.6 m/HARPS, and OHP-1.93/ELODIE instruments. The K2 time-series photometry was analysed with the jktebop code, with out-of-eclipse modulations of different origin taken into account. Individual component spectra were retrieved with the fd3 code, and analysed with the code ispec in order to determine effective temperatures and metallicities. Absolute values of masses, radii, and other stellar parameters are calculated, as well as ages, found through isochrone fitting. For five systems, such analysis has been done for the first time. The presented sample consists of a variety of stars, from low-mass dwarfs, through G- and F-type main sequence objects, to evolved active sub-giants, one of which is found to be crossing the Hertzsprung gap. One target may contain a γ Dor-type pulsator, two more are parts of higher-order multiples, and spectra of their tertiaries were also retrieved and used to constrain the properties of these systems.
We report the discovery of two transiting extrasolar planets by the HATSouth survey. HATS-9b orbits an old (10.8 + or - 1.5 Gyr) V = 13.3 G dwarf star with a period P approximately 1.9153 days. The ...host star has a mass of 1.03 M sub(odot), radius of 1.503 Rodot, and effective temperature 5366 + or - 70 K. The planetary companion has a mass of 0.837 M sub(J) and radius of 1.065 R sub(J), yielding a mean density of 0.85 g cm super(-3). HATS-10b orbits a V = 13.1 G dwarf star with a period P approximately 3.3128 days. The host star has a mass of 1.1 M sub(odot), radius of 1.11 R sub(odot), and effective temperature 5880 + or - 120 K. The planetary companion has a mass of 0.53 M sub(J) and radius of 0.97 R sub(J), yielding a mean density of 0.7 g cm super(-3). Both planets are compact in comparison with planets receiving similar irradiation from their host stars and lie in the nominal coordinates of Field 7 of K2, but only HATS-9b falls on working silicon. Future characterization of HATS-9b with the exquisite photometric precision of the Kepler telescope may provide measurements of its reflected light signature.
Decision aids (DAs) are evidence-based tools that support shared decision-making (SDM) implementation in practice; this study aimed to identify existing osteoporosis DAs and assess their quality and ...efficacy; and to gain feedback from a patient advisory group on findings and implications for further research. We searched multiple bibliographic databases to identify research studies from 2000 to 2019 and undertook an environmental scan (search conducted February 2019, repeated in March 2020). A pair of reviewers, working independently selected studies for inclusion, extracted data, evaluated each trial’s risk of bias, and conducted DA quality assessment using the International Patient Decision Aid Standards (IPDAS). Public contributors (patients and caregivers with experience of osteoporosis and fragility fractures) participated in discussion groups to review a sample of DAs, express preferences for a new DA, and discuss plans for development of a new DA. We identified 6 studies, with high or unclear risk of bias. Across included studies, use of an osteoporosis DA was reported to result in reduced decisional conflict compared with baseline, increased SDM, and increased accuracy of patients’ perceived fracture risk compared with controls. Eleven DAs were identified, of which none met the full set of IPDAS criteria for certification for minimization of bias. Public contributors expressed preferences for encounter DAs that are individualized to patients’ own needs and risk. Using a systematic review and environmental scan, we identified 11 decision aids to inform patient decisions about osteoporosis treatment and 6 studies evaluating their effectiveness. Use of decision aids increased accuracy of risk perception and shared decision-making but the decision aids themselves fail to comprehensively meet international quality standards and patient needs, underpinning the need for new DA development.
PDF
